

"Tests as part of a wider system" Chris Hudson

Director of Healthcare Development - Roche Diagnostics Ltd





"Tests as part of a wider system" Chris Hudson

Director of Healthcare Development - Roche Diagnostics Ltd





"In Vitro Diagnostics Tests as part of a wider system" Chris Hudson

Director of Healthcare Development - Roche Diagnostics Ltd





Challenges of the NHS...

History...the predictor of the future?

Diesels V Bullets?

Isolationism rules?

Change of focus?

Roche

Real life in todays NHS...

A patients story....today's NHS

- Jim aged 87 ex NHS dentist
- Health history
 - Diabetes T2 15 years
 progressive controlled with tablets
 - CHF 5 years Stented & diuretics
 - Renal issues 25 years...
- Recent health history (8 weeks)
 - Taken off diuretics 8 weeks ago advice to GP from Nephrologist.
 - Admitted to hospital 3 weeks ago
 - CHF diagnosed & back on diuretics.



Is he one of the @3% of patients that use @45% of CCGs budgets?



Real life in todays NHS...

Provider's and commissioner's what's the rough economics of the deal to them and then to the NHS

Commissioner (CCG)

Savings

Eight weeks diuretics£50

Expenditure

- Payment to hospital -£?
 to provider under contract
- No transparency -but less cost than the Acute trust

Total (loss) to CCG

-£?

Provider (Acute Trust)

Savings /income CCG

CCG payment £ 1

Expenditure

- A & E admission £(233)
- AMU 5 x days $\pounds(1,726)$
- CCU 16 x days£(5,788)
- Catheterisation 15 x days£(1,838)
- Other Costs BgM, Oxygen

Source: National Schedule of Reference Costs Year: 2014-15 - NHS trusts and NHS foundation to



How Many "Jims" might there be in the £2.45bn NHS overspend in 2015-2016?

£2.45bn /£10,554 = 232,139 "Jims"

- •1,507 average per Acute Trust (154)
 - 29 per week per trust
- •1,110 average per CCG (209)
 - 21 per week per CCG

Thoughts

- Does this "silo" budgeting/patient management mentality really work?
- •"Penny wise and pound foolish"
- •Joined up thinking needed "common sense" too ?
- •Money following the patient & IT systems to support the flow!



Is he one of the @3% of patients that use @45% of CCGs budgets?



Challenges of the NHS...

History...the predictor of the future?

Diesels V Bullets?

Isolationism rules?

Change of focus?



History ... a "predictor of the future"

Is the NHS, the "Death Valley" for uptake of innovation?


Troponin Testing

- 25 years for widespread adoption in UK
- Still large variations in usage
- "In the 19 years of clinical practice the only test that changed in the "routine" panel was CKMB for Troponin"

Sir John Savill CEO MRC Dec 2015

Thought to consider

In the UK we "Innovate" and "Evaluate" well but do we then ADOPT?






Challenges of the NHS...

History...the predictor of the future?

Diesels V Bullets?

Isolationism rules?

Change of focus?







High Sensitivty Troponin

- •25 years of Troponin testing "history"
- New Troponin test giving a result at
 1 hour v's 3 hours fantastic
 technological advance !
- •Introduced 5 years ago price same as "Old" Troponin.

Opportunity to:

- •Improve clinical practice, patient treatment and patient outcome.
- •Reduce strain on stretched A&E and specialist resources.
- •Improve value for everyone.

So what has happened with HS Troponin?



Patients and the system will have to wait for better care...





Outcome - 5 years later

- •NICE positive endorsement 2014 but its only a "guideline" only for Diagnostics WHY?
- •Only 20% sites are utilising the HS Troponin

Potential Conclusions?

- •New "tools" are available to significantly improve clinical practice, patient outcome &, use of scarce resources with NO increase in cost overall "Value" significantly increased
- •The NHS does not have the WILL nor CAPACITY to change?
- •Change Management is the "missing" piece ?
- •"Empowered Champions" needed ?
- •All of the above?

Pre Eclampsia



A major opportunity to change clinical practice in maternal health



Situation

- Been available for nearly 3 years
- NICE guidance May 2016
- John Radcliffe Oxford only hospital in UK that has implemented ..so far
- Sites asking to do studies to validate for "local population" -WHY?
- What will be the future for this innovation?



Challenges of the NHS...

History...the predictor of the future?

Diesels V Bullets?

Isolationism rules?


Change of focus?

The "technology" seems to be THE focus on IVDs The discussion should be on the VALUE to the whole system

Patients are treated in "care pathways"

NICE

- "Health Technology Assessment"
- The Value delivered to the whole system is not considered.
- Assessment is *Guidance only* not Mandatory like Medicines.
- No measurement of *implementation* Innovation scorecards have less
 than 10 IVDs, whereas Medicines are
 60+.
- No *funding* to change clinical services
- No support for IMPLEMENTATION



Resolving the problems of the NHS requires thinking on a wider scale than just "technology" and "costs"

Roche

Map illustrative only

Doing more of the same is NOT the answer to a system challenged by cost

•Example:

- Acute Trust at tender for Pathology: £20mn trust deficit
- Problem: too many elderly patients ("Jims") coming from local CCGs - "bed blocking", using expensive resource

Potential Solutions

- Cut £1mn Pathology budget by 20%£200k but doesn't reduce the underlying REAL problem of "Jims" coming from the CCG!
- Or cut the number of "Jims" by using changing Patient pathway (outreach Dx clinics) testing closer to the patient changing the pathways to reduce admissions e.g. NT ProBNP
- •Health economics needed to look at Budget Impact on the change the health and wellbeing system (patient pathway and test) NOT just "cost effectiveness".





Challenges of the NHS...

History...the predictor of the future?

Diesels V Bullets?


Isolationism rules?

Change of focus?



Revaluing In Vitro Diagnostics

In vitro diagnostics testing has long been a silent champion of healthcare:



Source: European Diagnostic Manufacturers Association (EDMA) 2009



The value of in vitro diagnostics Improving health, influencing smart spending

Disease prevention Right treatment decision Disease management

Screening Diagnosis Prognosis Stratification Monitoring

Information

- Keeping people healthy
- Getting the right treatment
- Stopping a patient from getting worse
- Chronic disease management


- Increasing efficacy of treatment
- Eliminating trial and error
- Reducing hospitalization
- Avoiding work productivity loss

Improving people's health

Influencing smart healthcare spending & saving healthcare costs



Diagnostics are about gathering medical data To be transformed into actionable information



Critical Success Factor:

Need patient EHR systems that are complete & join it all up - GeL model?

The NHS system needs a change of approach Four core concepts for success...





Listen to and involve - the wider "stakeholder" groups e.g. Patients, Industry



Focus and prioritise -on what really matters FAST and **deliver VALUE**



Simplify - make process of NICE adoption **Mandatory**, **Measured**, **Funded**



Leverage expertise - internal & external e.g. Change Management & Best Practice Sharing



Challenges of the NHS...

History...the predictor of the future?


Diesels V Bullets?

Isolationism rules?

Change of focus?



In Vitro Diagnostics - The Roche view The power of knowing for better patient care



Improving people and patients' lives and making healthcare sustainable



Roche what we believe

Working together, creating value for all...

Within the next five years, Roche Diagnostics' unique pioneering approach will have fundamentally changed the way patients are managed by ensuring in vitro diagnostics are always at the heart of care pathways and at the forefront of clinicians' decisions – resulting in better patient outcomes



Roche Diagnostics - our view

Working together, creating value for all

We will try to:



Enable the NHS to achieve their objectives and targets more effectively.



Create value for Clinicians, Trusts, CCGs, patients and the wider healthcare system.



Clearly differentiate to the NHS why they should choose Roche.



There is hope!

Accelerated Access Review (AAR) - launched March 2015



Accelerated Access Review

Contents

- What we do
- Corporate information

Accelerated Access Review homepage

About us

What we do

The Accelerated Access Review aims to speed up access to innovative drugs, devices and diagnostics for NHS patients.

There are many benefits from achieving this goal, including:

- patients will have access to, and be treated with, cutting-edge medical products sooner
- research organisations, patient groups and charities will be able to be an integral part of the process for developing new products from the outset
- clinicians will be able to support their patients to access more effective and affordable innovative treatments and achieve better health
- businesses will benefit as a result of a simpler, better and more joined up development pathway for medicines, devices and digital healthcare
- stimulation of new investment, jobs and economic growth to support the NHS

The Accelerated Access Review is considering medicines, devices and diagnostics. Three potential areas of reform have been identified: regulation, reimbursement and uptake.

- Interim Report Oct 2015
- Great deal of "hope" around this review.
 - "Innovation Partnerships"
 - "Innovation Pathways"
- "Galvanising the NHS to adopt innovation" - May 2016
 - AHSNs fund to encourage system redesign
 - Clinical system leaders to champion change
 - Secondary Care "Innovation champions"
- Final report recommendations July 2016



What is my ask of you?

No one person or group can solve this on their own



- Industry can give the NHS lots of new "magic bullet" technology innovations..
- By working together we can help the NHS get the most Value out of new technology by looking at the wider system.

What I would like to ask you to do?

- •Challenge Status Quo
- •Ask "How do we implement quickly"?
- Keep asking "Why not"
- •Empower and experiment

And here's WHY

"Jim" & others like him, are relying on the NHS.





Doing now what patients need next